MannKind Corporation (MNKD) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-26

How it makes money

It earns revenue by selling proprietary inhaled and infused treatments directly in the United States and through collaboration partners elsewhere.

The company operates a cardiometabolic and orphan lung disease portfolio featuring commercial products like Afrezza, Furoscix, and V-Go, alongside development partnerships.

A significant portion of its revenue is derived from royalties and manufacturing fees paid by United Therapeutics for commercializing Tyvaso DPI, an inhaled treatment for pulmonary hypertension.

What protects it: the moat

It protects its market position using proprietary drug-device combination technologies, regulatory approvals, and strategic commercial partnerships across multiple jurisdictions.

Management asserts that its proprietary formulation and inhaler technologies, such as those utilized in Afrezza and Tyvaso DPI, provide competitive advantages in delivering therapies directly to the lungs or via subcutaneous devices.

However, these protective barriers rely heavily on continued market acceptance and the strategic resource allocation of commercial partners over whom the company has limited control.

What growth costs

It incurs ongoing reinvestment costs through clinical trials, regulatory submissions, manufacturing scale-up, and expanding commercial infrastructure for its therapeutic portfolio.

The filing does not provide a fixed aggregate capital expenditure figure for maintaining versus growing its operations, but details active investments in pipeline programs like MNKD-201 and regulatory applications such as supplemental NDAs and BLAs.

It also expands its portfolio through corporate transactions, such as the acquisition of scPharmaceuticals in October 2025 to obtain Furoscix.

What could damage it

A primary dependency on a single partner's commercial priorities could permanently impair earnings if that partner shifts focus to competing therapies.

Because a substantial portion of revenue stems from royalties and manufacturing tied to United Therapeutics, any strategic decision by that partner to prioritize alternative treatments, such as a newly developed solution, could materially reduce incoming cash flows.

Since the company maintains limited control over its partner's promotional activities and sales force deployment, such a shift would directly undermine its primary earnings engine without an immediate internal replacement.

About MannKind Corporation

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Other companies in Biotechnology